| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sven R Suwijn, Kora de Bruin, Rob M A de Bie, Jan Booi. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease. Parkinsonism & related disorders. vol 20 Suppl 1. 2014-07-11. PMID:24262177. |
imaging of the dopaminergic system with single photon emission computed tomography (spect), and particularly of the dopamine transporter (dat) located in the striatum, is a well accepted tool in clinical practice to confirm or exclude loss of nigrostriatal dopamine (da) neurons in patients suspected to suffer from parkinson's disease (pd). |
2014-07-11 |
2023-08-12 |
human |
| Kenneth Marek, John Seibyl, Shirley Eberly, David Oakes, Ira Shoulson, Anthony E Lang, Chris Hyson, Danna Jenning. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. vol 82. issue 20. 2014-07-10. PMID:24759846. |
to compare the clinical and imaging characteristics of those precept (parkinson research examination of cep-1347 trial) subjects with a scan without evidence of dopaminergic deficit (swedd) to those with dopamine transporter (dat) deficit scans at study baseline and during a 22-month follow-up. |
2014-07-10 |
2023-08-13 |
human |
| Nadella Kumudini, Addepally Umai, Yalavarthy Prameela Devi, Shaik Mohammad Naushad, Rukmini Mridula, Rupam Borgohain, Vijay Kumar Kutal. Impact of COMT H108L, MAOB int 13 A>G and DRD2 haplotype on the susceptibility to Parkinson's disease in South Indian subjects. Indian journal of biochemistry & biophysics. vol 50. issue 5. 2014-07-10. PMID:24772965. |
in view of documented evidence demonstrating the association of dopaminergic metabolism and neurotransmission with parkinson's disease (pd), a case-control study was conducted to investigate the impact of particular polymorphisms in the catechol o-methyl transferase (comt) h108l, monoamine oxidase b (maob) int 13 a>g, dopamine transporter 1 (dat1) a1215g, dopamine receptor d2 (drd2) taq1a, drd2 taq1b and drd2 taq1d genes on the susceptibility to pd. |
2014-07-10 |
2023-08-13 |
human |
| Ja-Hyun Bai. Dopamine signaling in food addiction: role of dopamine D2 receptors. BMB reports. vol 46. issue 11. 2014-07-09. PMID:24238362. |
dopamine (da) regulates emotional and motivational behavior through the mesolimbic dopaminergic pathway. |
2014-07-09 |
2023-08-12 |
human |
| Roshni Baby Thomas, Shilpa Joy, M S Ajayan, C S Paulos. Neuroprotective potential of Bacopa monnieri and Bacoside A against dopamine receptor dysfunction in the cerebral cortex of neonatal hypoglycaemic rats. Cellular and molecular neurobiology. vol 33. issue 8. 2014-07-08. PMID:23975094. |
we investigated the alterations in dopaminergic functions by studying the dopamine d1 and d2 receptor subtypes. |
2014-07-08 |
2023-08-12 |
rat |
| Daniel E Rusynia. Neurologic manifestations of chronic methamphetamine abuse. The Psychiatric clinics of North America. vol 36. issue 2. 2014-07-03. PMID:23688691. |
by increasing the extracellular concentrations of dopamine while slowly damaging the dopaminergic neurotransmission, meth is a powerfully addictive drug whose chronic use preferentially causes psychiatric complications. |
2014-07-03 |
2023-08-12 |
Not clear |
| Gian Marco Leggio, Salvatore Salomone, Claudio Bucolo, Chiara Platania, Vincenzo Micale, Filippo Caraci, Filippo Drag. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. European journal of pharmacology. vol 719. issue 1-3. 2014-07-02. PMID:23872400. |
dopamine d3 receptor expression and function are both down-regulated in stress and depression, and these changes are reversed by antidepressant treatments, suggesting that enhanced dopaminergic neurotransmission mediated by dopamine d3 receptor participates in adaptive changes related to antidepressant activity. |
2014-07-02 |
2023-08-12 |
Not clear |
| Simone A van den Berge, Miriam E van Strien, Elly M Ho. Resident adult neural stem cells in Parkinson's disease--the brain's own repair system? European journal of pharmacology. vol 719. issue 1-3. 2014-07-02. PMID:23872414. |
one important pathological process in the brain of parkinson disease (pd) patients is the degeneration of the dopaminergic neurons in the substantia nigra, which leads to a decline in striatal dopamine levels and motor dysfunction. |
2014-07-02 |
2023-08-12 |
human |
| Simone A van den Berge, Miriam E van Strien, Elly M Ho. Resident adult neural stem cells in Parkinson's disease--the brain's own repair system? European journal of pharmacology. vol 719. issue 1-3. 2014-07-02. PMID:23872414. |
therefore, restoring the dopamine levels in the striatum of pd patients through stimulating endogenous nscs in the nearby svz to migrate into the striatum and differentiate into dopaminergic neurons might thus be an attractive future therapeutic approach. |
2014-07-02 |
2023-08-12 |
human |
| Simone A van den Berge, Miriam E van Strien, Elly M Ho. Resident adult neural stem cells in Parkinson's disease--the brain's own repair system? European journal of pharmacology. vol 719. issue 1-3. 2014-07-02. PMID:23872414. |
furthermore, we will summarise the reports that describe efforts to stimulate nscs to replace dopaminergic cells in the sn and restore striatal dopamine levels. |
2014-07-02 |
2023-08-12 |
human |
| Aracely Garcia-Garcia, Annandurai Anandhan, Michaela Burns, Han Chen, You Zhou, Rodrigo Franc. Impairment of Atg5-dependent autophagic flux promotes paraquat- and MPP⁺-induced apoptosis but not rotenone or 6-hydroxydopamine toxicity. Toxicological sciences : an official journal of the Society of Toxicology. vol 136. issue 1. 2014-07-01. PMID:23997112. |
dopaminergic cell death induced by the mitochondrial complex i inhibitors 1-methyl-4-phenylpyridinium (mpp⁺) and rotenone, the pesticide paraquat, and the dopamine analog 6-hydroxydopamine (6-ohda) was paralleled by increased autophagosome accumulation. |
2014-07-01 |
2023-08-12 |
Not clear |
| . Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 13. 2014-06-27. PMID:24123224. |
to establish a dosage of isradipine controlled-release (cr) that is tolerable and demonstrates preliminary efficacy for use in a future pivotal efficacy trial a phase 2, randomized, double-blind, parallel group trial (safety, tolerability and efficacy assessment of dynacirc cr in parkinson disease [steady-pd]) was undertaken in subjects with early pd not requiring dopaminergic therapy (dopamine agonists or levodopa) randomized 1:1:1:1 to 5, 10, or 20 mg of isradipine cr or matching placebo daily. |
2014-06-27 |
2023-08-12 |
human |
| Sandra Shi, Catherine Leites, Deli He, Daniel Schwartz, Winton Moy, Jianxin Shi, Jubao Dua. MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant. The Journal of biological chemistry. vol 289. issue 19. 2014-06-27. PMID:24675081. |
most antipsychotic drugs influence dopaminergic transmission through blocking dopamine receptors, primarily drd2. |
2014-06-27 |
2023-08-12 |
human |
| Mette Buhl Callesen, Jørgen Scheel-Krüger, Morten L Kringelbach, Arne Mølle. A systematic review of impulse control disorders in Parkinson's disease. Journal of Parkinson's disease. vol 3. issue 2. 2014-06-25. PMID:23938342. |
throughout the past decade it has been recognized that dopaminergic medication administered to remedy motor symptoms in parkinson's disease is associated with an enhanced risk for impulse control disorders and related compulsive behaviors such as hobbyism, punding, and the dopamine dysregulation syndrome. |
2014-06-25 |
2023-08-12 |
Not clear |
| Nicolas W Schuck, Peter A Frensch, Brit-Maren M Schjeide, Julia Schröder, Lars Bertram, Shu-Chen L. Effects of aging and dopamine genotypes on the emergence of explicit memory during sequence learning. Neuropsychologia. vol 51. issue 13. 2014-06-25. PMID:24035787. |
together our findings show that variations in genotypes relevant for dopamine functions are associated more with aging-related impairments in the explicit than the implicit component of sequence learning, providing support for theories emphasizing the role of dopaminergic modulation in cognitive aging and the magnification of genetic effects in human aging. |
2014-06-25 |
2023-08-12 |
human |
| Nathaniel S Miller, Youngbin Kwak, Nicolaas I Bohnen, Martijn L T M Müller, Praveen Dayalu, Rachael D Seidle. The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease. Behavioural brain research. vol 257. 2014-06-25. PMID:24076152. |
these findings provide further evidence for the role of the basal ganglia and dopamine in duration production and suggest that the degree of striatal dopaminergic denervation may explain the heterogeneity of performance between pd patients on the sensorimotor synchronization task. |
2014-06-25 |
2023-08-12 |
Not clear |
| Un Ju Jung, Eunju Leem, Sang Ryong Ki. Naringin: a protector of the nigrostriatal dopaminergic projection. Experimental neurobiology. vol 23. issue 2. 2014-06-25. PMID:24963276. |
parkinson's disease is the second most common neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons and a biochemical reduction of striatal dopamine levels. |
2014-06-25 |
2023-08-13 |
human |
| Jonathan Wiso. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Frontiers in neurology. vol 4. 2014-06-24. PMID:24109471. |
it binds competitively to the cell-membrane dopamine (da) transporter and is dependent on catecholaminergic (dopaminergic and adrenergic) signaling for its wake-promoting effects. |
2014-06-24 |
2023-08-12 |
Not clear |
| Michele Poletti, Ubaldo Bonuccell. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Therapeutic advances in psychopharmacology. vol 3. issue 2. 2014-06-24. PMID:24167681. |
the spatiotemporal progression of dopamine depletion in parkinson's disease (pd) provides a special model for assessing dopaminergic effects on neural systems with differential baseline dopamine levels. |
2014-06-24 |
2023-08-12 |
Not clear |
| Michele Poletti, Ubaldo Bonuccell. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. Therapeutic advances in psychopharmacology. vol 3. issue 2. 2014-06-24. PMID:24167681. |
while considering dopaminergic drugs (levodopa or dopamine agonists), temporal intervals (acute or chronic) and cognitive domains, we found that empirical evidence was almost focused on acute effects of levodopa on executive functions. |
2014-06-24 |
2023-08-12 |
Not clear |